Global Exosome Therapeutics Market – Industry Trends and Forecast to 2030

Exosome Therapeutics Market Analysis and Size

As per the records of WHO, cancer is a top cause of death worldwide, resulting in around 10 million deaths in 2020. This increasing cancer prevalence is demanding more exosome research. The increasing demand for fast, accurate, and minimally invasive diagnostic procedures shows a massive opportunity for the growth of exosome applications. The growing number of articles leading to exosomal research is boosting R&D activities in the field.

Data Bridge Market Research analyses that the exosome therapeutics market, which was USD 550.58 thousand in 2022, would rise to USD 1,986.86 thousand by 2030 and is expected to undergo a CAGR of 17.40% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Exosome Therapeutics Market Scope and Segmentation

Market Definition

The exosomes are a particular class of cell-derived extracellular vesicles composed of endosomes that are normally 30-150 nm in diameter. The exosomes have been connected to treat numerous chronic conditions such as autoimmune disorders. Since the exosomes offer strong potential for applicability in therapeutic interventions, the exosomes have been stated as potential drug carriers. In cancer, exosomes have huge roles in metastatic spread, drug resistance, and the formation of new blood vessels.

Global Exosome Therapeutics Market Dynamics

Drivers

• Increasing Incidence of Cancer

As per the records of WHO, cancer is the leading cause of mortality globally, resulting in about 10 million deaths in 2020. The number of cancer patients in India among males was about 679,421, and for females was nearly 712,758 in 2020. In 2021, the number of new cancer cases and deaths was around 1.9 million, and 608,570 cancer deaths in the U.S. Thus, cancer incidence is motivating physicians to do more and more research. Biomarker is helpful in the identification of cancer. Thus, the market growth is increased.

• Growing R&D Activities Associated with Exosome Research

The growing number of articles associated with exosomal research is enhancing R&D activities in the field. Currently, more than 4400 articles are published on exosomes, with around 25% of these published in 2016 alone. Along with the substantial rise in article publication, the huge range of companies widely engaged in research is also increasing. Additionally, an increase in funding for R&D is set to boost industrial growth positively.

Opportunities

• Increasing Developments by Market Players

Major market players have been increasing developments regarding exosome therapeutics, boosting the market growth. For instance, Cell Guidance Systems, a U.S.-based biotechnology research organization, declared plans for developing exosome therapeutics for treating COVID-19 disease in 2021. Furthermore, huge growth in government and non-government initiatives for exosome research will most likely enhance the growth during the study period.  

• Increase in Neurogenerative Disorders

Neurodegenerative diseases are the primary cause of disability and mortality, combined with an extensive financial burden on healthcare systems. According to the United Nations report, the number of dementia cases in highly emerging countries is expected to increase from 13.5 million in 2000 to 21.2 million in 2025 to 36.7 million in 2050. This increase is estimated to contribute to a rise in neurodegenerative diseases and an upsurge in the number of sophisticated exosome applications. This leads to the growth of the market.

Restraints/Challenges

• Contamination Associated with Exosomes

The contamination associated with exosomes leads to market growth reduction. If the exosomes are not properly extracted and sterilized, they can contain intracellular or extracellular genetic material. This genetic material can be very harmful. This can send wrong signals to cells, potentially causing abnormal development of cells at the target site or other areas in the body. Thus, this factor leads to market hindrance.

This exosome therapeutics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the exosome therapeutics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In  2021, Capricor Therapeutics entered into an agrrement with Johns Hopkins University to increase the exosome platform technology portfolio. The exosome platform technology portfolio includes engineered exosomes for vaccines and therapeutics as part of the company's exosome technology portfolio. The agreement would enable Capricor Therapeutics to get worldwide right to use exosomes for vaccines and therapeutics

Global Exosome Therapeutics Market Scope

The exosome therapeutics market is segmented on the basis of type, source, therapy, transporting capacity, application, route of administration, and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Natural
• Hybrid

Source

• Mesenchymal Stem Cells
• Blood, Body Fluids
•  Urine
• Dendritic Cells
• Saliva
• Milk
• Others

Therapy

• Immunotherapy
• Chemotherapy
• Gene Therapy

Transporting Capacity

• Bio Macromolecules
• Small Molecules

Application

• Metabolic Disorders
• Oncology
• Cardiac Disorders
• Neurology
• Inflammatory Disorders
• Organ Transplantation
• Gynecology Disorders
• Blood Disorders
• Others

Route of Administration

• Parenteral
• Oral

End-user

• Research and Academic Institutes
• Hospitals
• Diagnostic Centers

Exosome Therapeutics Regional Analysis/Insights

The exosome therapeutics market is analyzed and market size insights and trends are provided by type, source, therapy, transporting capacity, application, route of administration, and end user as referenced above.

The countries covered in the exosome therapeutics market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the exosome therapeutics market due to the wide presence of FDA-approved wound debridement devices, the availability of health remuneration policies, increase in chronic wounds, and growth in the elderly population. Also, the dominance of the natural exosomes segment is enhancing the market growth

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 due to growing expenditure on healthcare infrastructure, increasing investments for R&D activities, and focus of the government. Also, the increasing awareness regarding the treatment and incidence of infectious disease cases and ongoing clinical trials lead to market growth.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The exosome therapeutics market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for exosome therapeutics market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the exosome therapeutics market. The data is available for historic period 2011-2021.

Competitive Landscape and Global Exosome Therapeutics Market Share Analysis

The exosome therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to exosome therapeutics market.

Some of the major players operating in the exosome therapeutics market are:

• Church & Dwight Co., Inc. (U.S.)
• GSK plc. (U.K.)
• Pfizer Inc. (U.S.)
• Sun Pharmaceutical Industries Ltd. (India)
• Takeda Pharmaceutical Company Limited (Japan)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Novartis AG (Switzerland), Lily. (U.S.
•  AstraZeneca (U.S.)
• Boehringer Ingelheim International GmbH (Germany)
• CELGENE CORPORATION (U.S.)
• Sanofi (France)
• Johnson & Johnson Services, Inc. (U.S.)
• Dr. Reddy's Laboratories Ltd. (India),
• Teva Pharmaceutical Industries Ltd. (Israel)
• Bristol-Myers Squibb Company (U.S.)

SKU-50629